Sheng Yang

Dr. Sheng Yang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Translational Oncology
Verified
Journal Article
Open access
XHXiaohong Han
Xiaohong Han
ZZZhishang Zhang
Zhishang Zhang
DWDi Wu
Di Wu
YSYinchen Shen
Yinchen Shen
SWShuai Wang
Shuai Wang
YSYuan-kai Shi
Yuan-kai Shi
Epidermal growth factor receptor (EGFR) mutation status is crucial in treatment selection for non-small cell lung cancer (NSCLC) patients; however, the detection materials' availability remains challenging in clinical practice. In this study, we collected surgical resection tissues, lymph node biopsy, and cytological samples for EGFR mutation testing and investigated the associations between gene mutation and clinical characteristics. Two hundred and seventy-six NSCLC adenocarcinoma specimens were collected, and highly sensitive amplification refractory mutation system method was implemented for EGFR mutation detection, with clinicopathologic characteristics involved in the final analysis. In the total of 276 samples, 96% (265/276) of tumors obtained evaluable EGFR mutation status, the frequency of mutation was 55.8% (148/265) in all specimens, and three different type samples shared a comparable successful testing rate: 97.4% (38/39) in surgical tumor tissues, 100% (108/108) in lymph node biopsy samples, and 92.2% (119/129) in cytological samples. EGFR mutation was significantly associated with sex, smoking history, lymph node metastasis status (N stage), primary tumor size, testing tissues origin, and sample type (P < .05). Multivariate analysis reconfirmed that smoking history and primary tumor size shared significant correlation with EGFR mutation after adjustment. Both lymph node biopsy and cytological samples were suitable surrogates for EGFR mutation detection in NSCLC compared with tumor tissues, gene status should be detected widely considering the high EGFR mutation rate, and nonsmoking history together with smaller primary tumor size was an independent indicator of EGFR mutation status.

14 September 2015 in Chinese Journal of Cancer
Verified
Journal Article
Open access
PDF file
YSYuan-kai Shi
Yuan-kai Shi
PZPing Zhou
Ping Zhou
XHXiaohong Han
Xiaohong Han
XHXiaohui He
Xiaohui He
SZShengyu Zhou
Shengyu Zhou
SZShuxiang Zhang
Shuxiang Zhang
The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin’s lymphoma (NHL). This study aimed to assess the efficacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients. Factors affecting the collection of CD34+ cells were also explored. Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were financially eligible received R-CHOP for autologous peripheral blood stem cell (APBSC) mobilization; the remaining 25 patients received CHOP. The median CD34+ cell yield was 7.01 × 106 cells/kg body weight (range 1.49–28.39 × 106 cells/kg body weight), with only two patients failing to meet the target CD34+ cell harvest of ≥2.0 × 106 cells/kg body weight. The median number of apheresis procedures per patient was 1 (range 1–3). The APBSC mobilization yield of the CHOP group appeared to be higher than that of the R-CHOP group (P = 0.005), whereas the success rate was similar between groups. R-CHOP elevated the complete response (CR) rate in B cell lymphoma patients as compared with CHOP (P = 0.01). No significant differences in toxicity or engraftment were observed between the two groups. The present study demonstrated that dose-adjusted CHOP chemotherapy effectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma.

16 April 2018 in BMC Immunology
Verified
Journal Article
Open access
PDF file
PXPuyuan Xing
Puyuan Xing
HWHongyu Wang
Hongyu Wang
Sheng YangSheng Yang
Sheng Yang
XHXiaohong Han
Xiaohong Han
YSYan Sun
Yan Sun
YSYuan-kai Shi
Yuan-kai Shi
Hu-rhEGF-rP64k/Mont is a biotechnology product for the treatment of advanced non-small cell lung cancer (NSCLC). The vaccine induces a neutralizing antibody-mediated immune response, against the normal circulating self-protein antigen epidermal growth factor (EGF), which prevents its binding to and activation of the EGF receptor, inhibiting the transduction of the signals that drive cancer cell proliferation, survival and spread. This phase I study aimed to evaluate the safety and the immunological response of Hu-rhEGF-rP64k vaccine in NSCLC patients. The Hu-rhEGF-rP64k/Mont vaccine showed to be safe and well tolerated, with dizziness, injection-site reactions and tremors being the most commonly reported adverse event. No severe adverse events or death were related to the vaccination. Immune monitoring demonstrated the generation of anti-EGF antibody titers and as a consequence the patients exhibited a decrease in the EGF concentration. In 80% of the vaccinated patients stable disease was achieved. Hu-rhEGF-rP64k/Mont elicited a valuable immune response, with good safety profile assuring further clinical development of the vaccine in this population to further confirm the potential benefits on survival. Chinese Clinical Trial Registry, ChiCTR-OID-17014048 , date 2017/12/20 (retrospectively registered); Chinese Food and Drug Administration, CFDA 2009 L02105, date 2009/04/03; China Drug Trial, CTR20131039 .

16 March 2026 in Cancer Innovation
Verified
Journal Article
Open access
PDF file
MXMengqing Xie
Mengqing Xie
MYMeng Yuan
Meng Yuan
MRMengwei Ren
Mengwei Ren
JTJing Tian
Jing Tian
SZShengyu Zhou
Shengyu Zhou
SLSidan Li
Sidan Li
Background: To evaluate the efficacy and safety of novel chemotherapy regimens, including brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs), in children, adolescents, and young adults (CAYA) with Hodgkin lymphoma (HL). Methods: A retrospective analysis was conducted on untreated Stage IIB (bulky), III, or IV HL patients (≤ 24 years) who were admitted to Cancer Hospital of the Chinese Academy of Medical Sciences and Beijing Children's Hospital, Capital Medical University, from 2017 to 2024. The cohort compared conventional regimens with BV‑based therapies (BV‑AVD ± R). Furthermore, the efficacy and safety of ICIs were evaluated in relapsed/refractory cHL patients receiving second‑line or later therapy. Results: In this comparison between BV and conventional regimens, 182 patients were enrolled. The median follow‐up was 38 months. No significant differences were observed in objective response rate (ORR) (96.4% vs 95.4%, p = 0.927) or progression‐free survival (PFS) rate (92.8% vs 95.3%, p = 0.466).However, the incidence of Grade 4 hematologic toxicity was significantly higher with conventional therapy compared to BV‐AVD±R (61.2% vs 25.6%, p < 0.001). The BV‐AVD group alone achieved a significantly higher ORR than the BV ‐AVD+R group (100% vs. 93.9%, p = 0.047), while there was no significant difference in PFS rate. However, the BV‐AVD + R group exhibited a significantly higher incidence of Grade 3–4 hematologic toxicities (78.8% vs. 20.0%, p = 0.023). Immune checkpoint inhibitors was well‐tolerated with infrequent adverse events, and 18/19 cases (94.7%) demonstrated treatment efficacy. Conclusion: For patients with stage II Hodgkin lymphoma presenting with bulky disease, as well as those with stage III–IV disease, the BV‐AVD regimen is recommended as first‐line therapy, given its more favorable toxicity profile.Although ICIs represent a promising therapeutic approach, existing studies are constrained by limited sample sizes. Future research should focus on expanding patient cohorts to refine treatment strategies and ultimately improve clinical outcomes.